Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014 , WKN: 905249

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Cerus Corporation to Participate in Upcoming Investor Conferences

2024-11-13
CONCORD, Calif., November 13, 2024--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.

Cerus Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

2024-11-01
Cerus ( NASDAQ:CERS ) Third Quarter 2024 Results Key Financial Results Revenue: US$46.0m (up 16% from 3Q 2023). Net...

Q3 2024 Cerus Corp Earnings Call

2024-10-31
Q3 2024 Cerus Corp Earnings Call

Cerus Corp (CERS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

2024-10-31
Cerus Corp (CERS) reports a robust 16% increase in product revenue and raises full-year guidance, while navigating supply chain issues and regulatory hurdles.

Cantor Fitzgerald Reaffirms Their Buy Rating on Cerus (CERS)

2024-10-31
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript

2024-10-30
Cerus Corporation (NASDAQ:CERS) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ETCompany ParticipantsJessica Hanover - VP, Corporate AffairsObi...

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

2024-10-30
Cerus (CERS) delivered earnings and revenue surprises of 33.33% and 4.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Discovering Opportunities: AlloVir And 2 Other US Penny Stocks

2024-10-30
As the U.S. stock market navigates a landscape shaped by mixed economic data and ongoing corporate earnings reports, investors are keenly observing potential opportunities across various sectors. Penny stocks, a term that may seem outdated, still capture the essence of investing in smaller or emerging companies with potential for growth. By focusing on those with strong financials and clear growth prospects, investors can uncover hidden gems amidst these lesser-known equities.

Cerus: Q3 Earnings Snapshot

2024-10-30
CERS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Concord, California-based company said it had a loss of 2 cents. The biomedical products company posted revenue of $46 million in the period.

Cerus Corporation Announces Third Quarter 2024 Financial Results

2024-10-30
CONCORD, Calif., October 30, 2024--Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024.